Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $65.64.

Several brokerages recently weighed in on IMCR. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $71.00 price target on shares of Immunocore in a research note on Wednesday, March 12th.

Immunocore Stock Down 1.1 %

IMCR stock opened at $29.32 on Friday. The firm’s fifty day moving average is $30.00 and its 200 day moving average is $31.02. The firm has a market cap of $1.47 billion, a PE ratio of -30.86 and a beta of 0.79. Immunocore has a one year low of $27.19 and a one year high of $66.00. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Insider Activity at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the company’s stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the purchase, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.10% of the stock is currently owned by insiders.

Institutional Trading of Immunocore

A number of institutional investors have recently bought and sold shares of IMCR. GSA Capital Partners LLP acquired a new position in Immunocore in the third quarter valued at approximately $406,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Immunocore by 7.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock valued at $13,297,000 after acquiring an additional 29,689 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after purchasing an additional 520,950 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Immunocore by 27.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 498,221 shares of the company’s stock valued at $15,510,000 after purchasing an additional 107,656 shares during the last quarter. Finally, HealthInvest Partners AB boosted its position in shares of Immunocore by 127.4% in the 3rd quarter. HealthInvest Partners AB now owns 54,060 shares of the company’s stock valued at $1,683,000 after purchasing an additional 30,282 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.